INDUSTRY NEWS

ANTERIOR CHAMBER ANGLE
NIDEK has launched the Anterior Chamber Angle (ACA) mode for the TONOPACHYTM NT-530P. “The Anterior Chamber Angle mode is a new feature included in the TONOPACHYTM NT-530P, the unique model combining Non Contact Tonometer and Pachymeter in one unit,” said a company spokesman.
The ACA mode allows the operator to capture an image of the anterior chamber angle with the Scheimpflug image. Along with the intraocular pressure, the visual observation of the anterior chamber angle further assists in the assessment of glaucoma.

 www.nidek.com

BEHIND THE SCENES 
The OCULUS company history film, telling the story of the company from 1895 to the present day, has been newly revised and is now available on the OCULUS website.
“Some 280 employees work in the areas of research and development, production, administration and sales at company headquarters in the Hessian city of Wetzlar (Germany),” said a company spokeswoman. 
“OCULUS employees who speak to visitors on factory tours often receive looks of incredulity when they talk about the wide range of manufacturing activity at the Wetzlar-based workshop, production and assembly facilities – much of which involves handcraft,” she said.
The video includes a section called “We are OCULUS – Have a glimpse behind the scenes”, where viewers can get a personal tour of the factory, meet some of its employees and learn about some of its work processes.
www.oculus.de/en/from-idea-to-product

NEW WEBSITE LAUNCHED

Quantel Medical has launched a new website to inform doctors about the benefits of using yellow wavelength light during surgeries. 
“The website will serve as a resource for interested ophthalmic professionals to learn more about Quantel Medical’s proprietary 577-nm MicroPulse® laser therapy, specifically about its applications in treating diabetic macular oedema (DME) and central serous chorioretinopathy (CSC),” said a company spokeswoman.
www.retina-yellow-laser-therapy.com

POSITIVE FISCAL YEAR
Carl Zeiss Meditec AG has reported a positive fiscal year. Revenue passed the billion mark in the fiscal year 2014/15, with a 14 per cent increase to €1,040 million, according to the company. Adjusted for currency effects, this equates to growth of around eight per cent over the previous year. Earnings before interest and taxes (EBIT) increased by eight per cent, to €130.6 million (previous year: € 120.7 million). “A strong fourth quarter and tailwind from the exchange rates of major currencies supported the good operating result,” said Dr Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.
www.zeiss.com

DIABETIC MACULAR OEDEMA
Allegro Ophthalmics has announced completion of enrollment in its DEL MAR Phase 2b trial that is evaluating the safety and efficacy of Luminate® (ALG-1001) in patients with diabetic macular oedema (DME). 
The company expects to report top-line data by the third quarter of 2016. “Completing the last patient enrolment in the DEL MAR trial on schedule represents another significant clinical development milestone for this drug candidate, and moves us a step closer to potentially bringing this new category of treatment forward to help DME patients,” said Vicken Karageozian MD, Chief Technical Officer, Allegro Ophthalmics, LLC. 
www.allegroeye.com